3rd PROGRAM

Day’s Theme: The Creative Process and Foundational Tools

 


 

  • 8:30 AM | Registration/Administrative Continental Breakfast

 


 

  • 9:00 AM | Session 1:  Welcome and Opening Remarks:

 

Prof. Asher Tishler, Dean, Faculty of Management, Tel Aviv University

Course Directors

 

Acknowledgement of Sponsors

 

Course Infrastructure:

 

Introduction to Program Structure

Review of required assignments

Formation of study teams

 


 

  • 9:30 AM | Session 2:  Opening Keynote Address

Introduction: Benny Zeevi, M.D. Managing General Partner, DFJ Tamir Fishman Ventures, Board IVA

 

Susan Berson, Managing Member of Mintz levin Washington, D.C. office

 

The impact of the Healthcare reform on the Healthcare Technological Innovation market.

 


 

  •    10.30 AM | Session 3: The Persuasive Pitch, Part 1: Introduction of course participants

 

Moderators: Kim Cooper – C.E.O, Kim Cooper Associates,    a communications consulting company

Benny Zeevi, M.D. Managing General Partner, DFJ Tamir Fishman Ventures, Board Member ILSI & IVA

 

In order to give participants a chance to learn more about their colleagues in the course, and as the first part of our special focus on presentations, we are asking each participant to prepare to deliver a 3-5 minute presentation, using 2-4 power point slides, to introduce yourself and your company to the group

 


 

  • 12:30 AM | Networking Luncheon

 


 

  • 13.30 PM | Session 4:   Lessons learned from our experience: A panel of life science serial entrepreneurs

In this session we will have several leading entrepreneurs in life science telling their experience

 

Moderators:  Brent\Benny Zeevi

Shimon Eckhouse, Co-founder and Chairman of Syneron Ltd. “Key success factors in new life science business ventures – a personal perspective”

 

 

Stan Rose, Ph.D former CEO of Nimblegen (acquired by Roche for $275M in August 2007), Genetic Microsystems (Affymetrix acquired for $175M in the early 2000’s)

 


 

  • 3:30 PM | Session 5: The Notion of a Business Model and a case study

 

Moderator: Brent Ahrens, General Partner, Canaan Partners

 


 

  • 5.00 PM | Bio – Break

 


 

 

  • 5:30 PM | Case Presentation- Pitch of one of the participants

 


 

 

  • 6:30 PM | Session 6: Market Analysis and Competitive Analysis – Essentials of Marketing in Biotechnology and Medical Devices

This session will focus on Market analysis, Clinical state of the art and product positioning: assessment of different applications for the same product (choosing the right application from commercial point of view), Determination of subgroup of patients most appropriate for the product, Competitive analysis, Pricing and reimbursement strategy, Importance of opinion leaders, patients groups, patients organization and  Selling strategy.

 

Moderator: Professor Stephen M.Sammut, Senior Fellow, Wharton Health Care Systems and Entrepreneurship and Venture Partner, Burrill & Company

 

 

David Frank, Managing Director MEDX ASSOCIATES LLC

 

Brent Ahrens, General Partner, Canaan Partners

 


 

  • 7:45 PM | Openning Dinner for Faculty and Participants

At the Green Vila, Tel Aviv University

Short lecture

 


Day’s Theme: Strategy and Execution


 

  • 8:30 AM | Continental Breakfast

 


 

  • 9:00 AM | Session 7: Biopharmaceutical and Medical Device Licensing, Partnering and Strategic Alliances

 

Format: Brief lectures, panel discussion, Q&A

 

Major practical issues in formulation of partnering goals and managing different types of strategic alliances,  preparation for positioning for partnering, identifying and qualifying prospective partners,  making the approach, negotiation, closing the deal, with special emphasis on how to design alliances and avoid many potential problems and complications in managing these relationship.

 

Moderator: Benny Zeevi

Session Keynote: Jeremy Levin M.D.,Ph.D. , Senior Vice President, Strategic Transactions., Bristol Myers-Squibb

 

Panelists:

 

Gad Berdugo, Managing Partner, Explorium Capital LLC, Former Director and Sector Leader for global healthcare equity investment research at Lazard in New York

 

Morris Laster, CEO,  BiolineRx Incubator

 

Maya Racine – Netser, Adv, Partner, Head, technology licensing group in the High Tech Practice ,  Herzog, Fox & Neeman

 


 

  • 11:00 AM | Bio Break

 


 

  • 11:30 AM | Session 8: Understanding Today’s  New Environment – Financing a Life Science Venture

Moderators:

Steve Sammut

 

Jeremy Levin, Jeremy Levin, M.D.,Ph.D , Senior Vice President, Strategic Transactions., Bristol Myers-Squibb

 

Brent Ahrens, General Partner, Canaan Partners

 

 

Andrew Farquharson, Managing Director, DFJ InCube Ventures

 

David Frank,  Managing Director MEDX ASSOCIATES LLC

 

Gad Berdugo, Managing Partner, Explorium Capital LLC, Former Director and Sector Leader for global healthcare equity investment research at Lazard in New York

 


 

  • 1:00 PM | Session 9: Case Presentation- Pitch of one of the participants

 


 

  • 1:30 PM | Networking Luncheon

 


 

 

  • 2:30 PM | Session 13: The Business Plan and the Pitch Book

 

Experienced entrepreneurs and their investors openly recognize that within a year of operating, few companies resemble their original business plan. Business plans and the accompanying pitch, however, provide the starting point of a shared vision and evidence that the founding team can reach a consensus in the business and technology development planning process and the resources required to meet critical milestones. The session provides a framework for developing a pitch and the essentials of a business plan. The session is structured in a novel way. An entrepreneur will present the pitch for his company to a panel of early stage biotechnology venture capitalists who will share real-time critique and recommendations. Boot Camp participants will be invited to share their own views as well.

 

Steve Sammut, Senior Fellow, Wharton Health Care Systems and Entrepreneurship and Venture Partner, Burrill & Company- “The Business Plan and the Pitch Book”

 

Brent Ahrens, General Partner, Canaan Partners

 

Andrew Farquharson, Managing Director, DFJ InCube Ventures

 


 

  • 3:30 PM | Session 11: Intellectual Capital Management

 

The goal of the session is to provide information and insight into the specific issues confronting investigators, entrepreneurs, investors and their patent attorneys. The session will address the formation of specific IP strategy and execution and using intellectual capital for competitive advantage. Content includes major issues confronting companies with US and filings in other jurisdictions related to biotechnology, e.g., patent ownership, non-obviousness rulings, the scope of what can be patented. In addition, a corporate representative will discuss IP portfolio management methods and how an IP portfolio relates to corporate strategy. A VC will also provide an investor viewpoint.

 

Moderator: Steve M.Sammut, Senior Fellow, Wharton Health Care Systems and Entrepreneurship and Venture Partner, Burrill & Company

 

 

Ivor Elrifi, Ph.D., LL.B. is Co-chair of the Intellectual Property Section and Member, Policy Committee Mintz Levin

 

 

Brent Ahrens, General Partner, Canaan Partners

 


 

  • 5:00 PM | Bio – Break

 


 

  • 5:30 PM | Session 12: 

 

Keynote lecture

 

Elezar Edelman, M.D., Ph.D. Director Harvard-MIT Biomedical Engineering Center

 

“Creating and Implementing Breakthrough Medical Technology” or the talk you gave: Academic-Industrial collaborative research in the modern ERA: The ups and the downs

 


 

  • 6.30 PM | Session 10: The Persuasive Pitch, Part 2: Presenting Your Idea—and Yourself—With Purpose, Clarity, and Power

 

Kim Cooper – C.E.O, Kim Cooper Associates, a communications consulting company

 


 

  • 8:00 PM | Adjourn for day

Day’s Theme: Building Value and Corporate Responsibility


 

  • 8:15 AM | Continental Breakfast

 


 

  • 8:45 AM : Keynote lecture:

 

Introduction: Benny Zeevi, M.D. Managing General Partner, DFJ Tamir Fishman Ventures, Board IVA

 

Keynote Theme: “Innovation in Interventional Cardiovascular Medicine: A Rapidly Moving Target!”

 

Martin Leon, M.D., Professor of Medicine, Associate Director, Center for Interventional Vascular Therapy, Columbia University Medical Center.

 


 

  • 9:45 AM | Session 14: Designing and Conducting Clinical Trials: From Proof of Concept to Marketing Success

 

This session provides an abbreviated view of the overall process and specific insight into planning for FDA regulations in light of strategy, financial needs, and the concerns of prospective partners and investors. Entrepreneurs need to understand that there is an increasing need to perform clinical studies to support medical device safety and performance claims. They also need to have a basic understanding of the activities, resources and costs associated with the design and conduct of clinical studies. The failure to incorporate an effective clinical strategy into new project planning can lead to significant project and funding delays or, worse, the failure of the project. This session will provide an overview of the increasing need for device clinical study data; key activities, resource needs and costs; and planning for the successful design and conduct of medical device clinical studies for acceptance in the United States and Europe, even when these studies are conducted outside of these regulatory jurisdictions.

 

Moderator: Robert Goldberg, PhD, Vice President, Center for Medicine in the Public Interest

 

 

Dr. Leonard Sacks, Deputy Director of the Office of Critical Path Programs from the FDA

 

Maria E. Donawa, M.D., President, Donawa Consulting, Medical Device Clinical Studies: Strategies for Success

 

Bruce Mackler, Senior advisor in FDA matters and FDA due diligence issues to financial/investment groups and companies.

 

 

Andy Weiss, President & CEO, CoAxia, former Vice President & General Manager of Medtronic Neurological.

 


 

  • 11:15 AM | Bio – Break

 


 

  • 11:45 AM | Session 15: Essentials of Pricing and Reimbursement

 

Moderator: Robert Goldberg, PhD, Vice President, Center for Medicine in the Public Interest

 

Lambert Van Der Walde, CMS, CMS liaison to VCs, start ups and Wall Street

Amir Inbar, CEO Mediclever, Reimbursement strategists in major European countries.

 

Susan Berson, Managing Member of Mintz levin Washington, D.C. office

 

Andy Weiss, President & CEO, CoAxia, former Vice President & General Manager of Medtronic Neurological.

 


 

  • 1:15 PM | Session 16: Case study on Pricing and Reimbursement or other case study

 

Moderator: Amir Inbar, CEO Mediclever,

 

Presenter: Adi Dagan, CEO of MCS

 


 

  • 1:45 PM | Luncheon

 


 

  • 2:15 PM | Session 17: Capitalization of a life science Venture –Terms, Rounds etc…

 

Andrew Farquharson, Managing Director, DFJ InCube Ventures

 

Andy Weiss, President & CEO, CoAxia, former Vice President & General Manager of Medtronic Neurological.

 

Alon Sahar,Adv., Partner,  Herzog, Fox & Neeman- Terms and agreements

 


 

  • 3:15 PM | Session 18: Post-luncheon Keynote :

Stan Rose, Ph.D former CEO of Nimblegen (acquired by Roche for $275M in August 2007), Genetic Microsystems (Affymetrix acquired for $175M in the early 2000’s)

 

“Successful Exit Strategies”

 


 

  • 3:45 PM | Session 19: Practical tips for CEOs, for survival and growth in tough financial environment- What not to do..and What to do

 

Moderator: Benny Zeevi, Managing Partner, DFJ Tamir Fishman Ventures

 

Israeli CEO’s- Prof’ Moshe Flugelman, President & CSO, MGVS

 

Andy Weiss, President & CEO, CoAxia, former Vice President & General Manager of Medtronic Neurological.

 

Brent Ahrens, General Partner, Canaan Partners

 


 

  • 4:30 PM | Bio – Break

 


 

  • 5:00 PM | Session 20: The Persuasive Pitch, Part 3: Presentations Workshop

 

Moderator: Kim Cooper – C.E.O, Kim Cooper Associates,    a communications consulting company

 

Three participants will present revised versions of their introductions from Sunday, and will receive feedback on both the written and spoken aspects of their presentations.

 


 

  • 6:00 PM | Program Adjournment

Session 21: Teams gather for “Take-aways Exercise”

 

Each participant will receive at registration a work-sheet to record for each session one major lesson or “take-away.” Teams will gather to discuss, compare notes, and develop one major take away for three sessions that will be assigned. Participants will have reviewed take-aways from Days 1 and 2 at the end of each day.

 


 

  • 6:45 PM | Program Adjournment